Hastings Cent Rep. 2020 May;50 Suppl 1(Suppl 1):S54-S61. doi: 10.1002/hast.1156.
The rise of genomic technologies has catalyzed shifts in the health care landscape through the commercialization of genome sequencing and testing services in the genomics marketplace. The development of consumer genomics into a growing array of information technologies aimed at collecting, curating, and broadly sharing personal data and biological materials reconstitutes the meaning of health and reframes patients into biocitizens. In this context, the good biocitizen is expected to assume personal responsibility for health through consumption of genomic information and acquiescence to public and private efforts at data surveillance and aggregation. These shifts raise fundamental questions about how competing interests of the public, the state, and corporate entities will be reconciled and what trade-offs are demanded for the promise of precision health.
基因组学技术的兴起通过基因组市场中基因组测序和检测服务的商业化，推动了医疗保健领域的变革。消费者基因组学发展成为一系列旨在收集、管理和广泛共享个人数据和生物材料的信息技术，重新定义了健康的含义，并将患者重塑为生物公民。在这种情况下，人们期望通过消费基因组信息并默许公共和私人的数据监测和聚合努力，来对自己的健康负责。这些转变引发了一些基本问题，即如何调和公众、国家和企业实体的利益冲突，以及为实现精准医疗需要做出哪些权衡。
